Evaluating Genertec Universal Medical Group’s Valuation After Its Latest Earnings And Share Price Reaction

Genertec Universal Medical Group (SEHK:2666) has drawn fresh attention after reporting full year 2025 earnings, with net income of CN¥2,208.95m and basic earnings per share from continuing operations of CN¥1.13. See our latest analysis for Genertec Universal Medical Group. The fresh full year 2025 earnings release has come alongside a 2.41% 1 day share price return to HK$5.95, while the 1 year total shareholder return of 21.34% contrasts with a slightly negative 90 day share price return of 3.41%. This suggests momentum has cooled after a stronger period for longer term holders. If this earnings move has you thinking about where else capital could work hard in healthcare, it may be a good moment to scan opportunities across 126 healthcare AI stocks With the shares trading at HK$5.95 and indicators such as intrinsic value and analyst targets suggesting a potential discount, the key question is whether this represents genuine value or whether the market is already pricing in future growth. Price to earnings of 4.8x: Is it justified? On a P/E of 4.8x, Genertec Universal Medical Group screens as cheap compared with both its own fair value estimates and the wider Hong Kong healthcare peer group. The P/E ratio compares the current share price to earnings per share and gives a quick sense of how much investors are paying for each unit of profit. For a company with CN¥2,208.95m in net income and a mixed set of growth forecasts, a lower P/E can point to the market applying a cautious earnings outlook, or simply not assigning a premium to its profile. Here, the contrast is quite sharp. Management has delivered earnings growth of 8.7% over the past year, beating its own 5 year average of 4.3% per year and outperforming an industry that saw a 17.3% earnings decline. Yet the shares trade on 4.8x earnings compared with a Hong Kong Healthcare industry average of 10.9x and an estimated fair P/E of 17x. That is a wide gap that the market could eventually close if the business keeps producing solid profits and cash flows. Explore the SWS fair ratio for Genertec Universal Medical Group Result: Price-to-Earnings of 4.8x (UNDERVALUED) However, the recent 30 day and 90 day share price declines, along with the diversified finance and healthcare model, could quickly challenge any simple undervaluation argument. Find out about the key risks to this Genertec Universal Medical Group narrative. Another angle on value The SWS DCF model points to a fair value of HK$9.23 per share, compared with the current HK$5.95 price. That implies a 35.5% discount, which supports the low 4.8x P/E signal but also raises a question: what assumptions need to break for this gap to stay open? Look into how the SWS DCF model arrives at its fair value. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Genertec Universal Medical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 236 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Curious whether the mix of risks and rewards here really adds up for you personally? Take a closer look at the underlying data, consider how it fits your goals and time horizon, then weigh the 4 key rewards and 1 important warning sign Looking for more investment ideas? If this stock has caught your eye, do not stop here. Broadening your watchlist can help you spot opportunities that better match your own approach. Target potential value opportunities by checking companies that appear mispriced on fundamentals through the 236 high quality undervalued stocks. Strengthen your focus on financial resilience by scanning companies with robust funding and low leverage in the solid balance sheet and fundamentals stocks screener (381 results). Hunt for potential up and comers with quality metrics on your side using the screener containing 589 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.